MRSA – what is it, and how do we deal with the problem?

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.9, Iss.2, 2005-04, pp. : 253-265

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

What are we looking for in new antibacterials and how do we design it?

By Barrett John F Motyl Mary

Expert Opinion on Investigational Drugs, Vol. 15, Iss. 2, 2006-02 ,pp. : 85-88

Informa Healthcare

Access to resources Recommend Favorite

"We Do What We Think Is the Best" - A Content Analysis of Experiences of Alcohol Problem Prevention in Sweden. A Short Report

By Blanck Per Hensing Gunnel Spak Fredrik

Substance Use & Misuse, Vol. 42, Iss. 12-13, 2007-10 ,pp. : 2073-2083

Informa Healthcare

Access to resources Recommend Favorite

We All Make Mistakes‐But What Can We Do About It?

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 32, Iss. 4, 2002-12 ,pp. : 261-262

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prevention and Pharmacovigilance: What Should We Do, What Can We Do?

By Edwards I. Ralph

Drug Safety, Vol. 35, Iss. 2, 2012-02 ,pp. : 87-90

Adis International

Access to resources Recommend Favorite

Neuropsychiatric Adverse Effects of Mefloquine: What Do We Know and What Should We Do?

By Nosten F.

CNS Drugs, Vol. 11, Iss. 1, 1999-01 ,pp. : 1-8

Adis International

Access to resources Recommend Favorite